# Evaluate the Preliminary Efficacy, Safety, and PK of Subcutaneous JS005 in Chinese Adult Patients With Active Nr-axSpA

> **NCT05242588** · PHASE2 · UNKNOWN · sponsor: **Shanghai Junshi Bioscience Co., Ltd.** · enrollment: 120 (estimated)

## Conditions studied

- Non-radiographic Axial Spondyloarthritis

## Interventions

- **BIOLOGICAL:** JS005
- **BIOLOGICAL:** Placebo

## Key facts

- **NCT ID:** NCT05242588
- **Lead sponsor:** Shanghai Junshi Bioscience Co., Ltd.
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-01-26
- **Primary completion:** 2023-04-01
- **Final completion:** 2023-06-10
- **Target enrollment:** 120 (ESTIMATED)
- **Last updated:** 2022-02-16

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05242588

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05242588, "Evaluate the Preliminary Efficacy, Safety, and PK of Subcutaneous JS005 in Chinese Adult Patients With Active Nr-axSpA". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT05242588. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*